- call +1-201-465-4211
- email sales@mrinsights.biz
Neurodegenerative diseases are becoming increasingly prevalent due to an aging population, but this diverse therapy area remains largely untreatable with current therapies. Neurodegenerative diseases are characterized by neuronal death within the brain and/or central nervous system (CNS), leading to progressive decline in functional neurological capacities. It has a devastating effect on quality of life and independence, often requiring full-time care during the later disease stages.
Scope of the Report:
This report focuses on the Neurodegenerative Diseases in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
The worldwide market for Neurodegenerative Diseases is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2023, from xx million US$ in 2017, according to a new study.
Market Segment by Manufacturers, this report covers
Novartis
Merck Serono
Teva Pharmaceutical
UCB
Pfizer
Biogen Idec
Bayer Schering Pharma AG
Boehringer Ingelheim
Addex Pharmaceutical
Amarin
AstraZeneca
Asubio Pharmaceutical
Bial
Alector
Yumanity Therapeutics
Eisai
H.Lundbeck A/S
Jiangsu Hansoh Pharmaceutical
Yangtze River Pharmaceutical Group
Chongqing Zein Pharmaceutical
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
NMDA
SSRIs
Dopamine Inhibitors
Market Segment by Applications, can be divided into
Parkinson’s disease
Huntington disease
Amyotrophic Lateral Sclerosis
Alzheimer’s disease
There are 15 Chapters to deeply display the global Neurodegenerative Diseases market.
Chapter 1, to describe Neurodegenerative Diseases Introduction, product scope, market overview, market opportunities, market risk, market driving force;
Chapter 2, to analyze the top manufacturers of Neurodegenerative Diseases, with sales, revenue, and price of Neurodegenerative Diseases, in 2016 and 2017;
Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017;
Chapter 4, to show the global market by regions, with sales, revenue and market share of Neurodegenerative Diseases, for each region, from 2013 to 2018;
Chapter 5, 6, 7, 8 and 9, to analyze the market by countries, by type, by application and by manufacturers, with sales, revenue and market share by key countries in these regions;
Chapter 10 and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2013 to 2018;
Chapter 12, Neurodegenerative Diseases market forecast, by regions, type and application, with sales and revenue, from 2018 to 2023;
Chapter 13, 14 and 15, to describe Neurodegenerative Diseases sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
Table of Contents
1 Market Overview
1.1 Neurodegenerative Diseases Introduction
1.2 Market Analysis by Type
1.2.1 NMDA
1.2.2 SSRIs
1.2.3 Dopamine Inhibitors
1.3 Market Analysis by Applications
1.3.1 Parkinson’s disease
1.3.2 Huntington disease
1.3.3 Amyotrophic Lateral Sclerosis
1.3.4 Alzheimer’s disease
1.4 Market Analysis by Regions
1.4.1 North America (United States, Canada and Mexico)
1.4.1.1 United States Market States and Outlook (2013-2023)
1.4.1.2 Canada Market States and Outlook (2013-2023)
1.4.1.3 Mexico Market States and Outlook (2013-2023)
1.4.2 Europe (Germany, France, UK, Russia and Italy)
1.4.2.1 Germany Market States and Outlook (2013-2023)
1.4.2.2 France Market States and Outlook (2013-2023)
1.4.2.3 UK Market States and Outlook (2013-2023)
1.4.2.4 Russia Market States and Outlook (2013-2023)
1.4.2.5 Italy Market States and Outlook (2013-2023)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
1.4.3.1 China Market States and Outlook (2013-2023)
1.4.3.2 Japan Market States and Outlook (2013-2023)
1.4.3.3 Korea Market States and Outlook (2013-2023)
1.4.3.4 India Market States and Outlook (2013-2023)
1.4.3.5 Southeast Asia Market States and Outlook (2013-2023)
1.4.4 South America, Middle East and Africa
1.4.4.1 Brazil Market States and Outlook (2013-2023)
1.4.4.2 Egypt Market States and Outlook (2013-2023)
1.4.4.3 Saudi Arabia Market States and Outlook (2013-2023)
1.4.4.4 South Africa Market States and Outlook (2013-2023)
1.4.4.5 Nigeria Market States and Outlook (2013-2023)
1.5 Market Dynamics
1.5.1 Market Opportunities
1.5.2 Market Risk
1.5.3 Market Driving Force
2 Manufacturers Profiles
2.1 Novartis
2.1.1 Business Overview
2.1.2 Neurodegenerative Diseases Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 Novartis Neurodegenerative Diseases Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.2 Merck Serono
2.2.1 Business Overview
2.2.2 Neurodegenerative Diseases Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 Merck Serono Neurodegenerative Diseases Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.3 Teva Pharmaceutical
2.3.1 Business Overview
2.3.2 Neurodegenerative Diseases Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 Teva Pharmaceutical Neurodegenerative Diseases Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.4 UCB
2.4.1 Business Overview
2.4.2 Neurodegenerative Diseases Type and Applications
2.4.2.1 Product A
2.4.2.2 Product B
2.4.3 UCB Neurodegenerative Diseases Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.5 Pfizer
2.5.1 Business Overview
2.5.2 Neurodegenerative Diseases Type and Applications
2.5.2.1 Product A
2.5.2.2 Product B
2.5.3 Pfizer Neurodegenerative Diseases Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.6 Biogen Idec
2.6.1 Business Overview
2.6.2 Neurodegenerative Diseases Type and Applications
2.6.2.1 Product A
2.6.2.2 Product B
2.6.3 Biogen Idec Neurodegenerative Diseases Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.7 Bayer Schering Pharma AG
2.7.1 Business Overview
2.7.2 Neurodegenerative Diseases Type and Applications
2.7.2.1 Product A
2.7.2.2 Product B
2.7.3 Bayer Schering Pharma AG Neurodegenerative Diseases Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.8 Boehringer Ingelheim
2.8.1 Business Overview
2.8.2 Neurodegenerative Diseases Type and Applications
2.8.2.1 Product A
2.8.2.2 Product B
2.8.3 Boehringer Ingelheim Neurodegenerative Diseases Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.9 Addex Pharmaceutical
2.9.1 Business Overview
2.9.2 Neurodegenerative Diseases Type and Applications
2.9.2.1 Product A
2.9.2.2 Product B
2.9.3 Addex Pharmaceutical Neurodegenerative Diseases Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.10 Amarin
2.10.1 Business Overview
2.10.2 Neurodegenerative Diseases Type and Applications
2.10.2.1 Product A
2.10.2.2 Product B
2.10.3 Amarin Neurodegenerative Diseases Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.11 AstraZeneca
2.11.1 Business Overview
2.11.2 Neurodegenerative Diseases Type and Applications
2.11.2.1 Product A
2.11.2.2 Product B
2.11.3 AstraZeneca Neurodegenerative Diseases Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.12 Asubio Pharmaceutical
2.12.1 Business Overview
2.12.2 Neurodegenerative Diseases Type and Applications
2.12.2.1 Product A
2.12.2.2 Product B
2.12.3 Asubio Pharmaceutical Neurodegenerative Diseases Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.13 Bial
2.13.1 Business Overview
2.13.2 Neurodegenerative Diseases Type and Applications
2.13.2.1 Product A
2.13.2.2 Product B
2.13.3 Bial Neurodegenerative Diseases Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.14 Alector
2.14.1 Business Overview
2.14.2 Neurodegenerative Diseases Type and Applications
2.14.2.1 Product A
2.14.2.2 Product B
2.14.3 Alector Neurodegenerative Diseases Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.15 Yumanity Therapeutics
2.15.1 Business Overview
2.15.2 Neurodegenerative Diseases Type and Applications
2.15.2.1 Product A
2.15.2.2 Product B
2.15.3 Yumanity Therapeutics Neurodegenerative Diseases Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.16 Eisai
2.16.1 Business Overview
2.16.2 Neurodegenerative Diseases Type and Applications
2.16.2.1 Product A
2.16.2.2 Product B
2.16.3 Eisai Neurodegenerative Diseases Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.17 H.Lundbeck A/S
2.17.1 Business Overview
2.17.2 Neurodegenerative Diseases Type and Applications
2.17.2.1 Product A
2.17.2.2 Product B
2.17.3 H.Lundbeck A/S Neurodegenerative Diseases Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.18 Jiangsu Hansoh Pharmaceutical
2.18.1 Business Overview
2.18.2 Neurodegenerative Diseases Type and Applications
2.18.2.1 Product A
2.18.2.2 Product B
2.18.3 Jiangsu Hansoh Pharmaceutical Neurodegenerative Diseases Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.19 Yangtze River Pharmaceutical Group
2.19.1 Business Overview
2.19.2 Neurodegenerative Diseases Type and Applications
2.19.2.1 Product A
2.19.2.2 Product B
2.19.3 Yangtze River Pharmaceutical Group Neurodegenerative Diseases Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.20 Chongqing Zein Pharmaceutical
2.20.1 Business Overview
2.20.2 Neurodegenerative Diseases Type and Applications
2.20.2.1 Product A
2.20.2.2 Product B
2.20.3 Chongqing Zein Pharmaceutical Neurodegenerative Diseases Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
3 Global Neurodegenerative Diseases Sales, Revenue, Market Share and Competition by Manufacturer (2016-2017)
3.1 Global Neurodegenerative Diseases Sales and Market Share by Manufacturer (2016-2017)
3.2 Global Neurodegenerative Diseases Revenue and Market Share by Manufacturer (2016-2017)
3.3 Market Concentration Rate
3.3.1 Top 3 Neurodegenerative Diseases Manufacturer Market Share in 2017
3.3.2 Top 6 Neurodegenerative Diseases Manufacturer Market Share in 2017
3.4 Market Competition Trend
4 Global Neurodegenerative Diseases Market Analysis by Regions
4.1 Global Neurodegenerative Diseases Sales, Revenue and Market Share by Regions
4.1.1 Global Neurodegenerative Diseases Sales and Market Share by Regions (2013-2018)
4.1.2 Global Neurodegenerative Diseases Revenue and Market Share by Regions (2013-2018)
4.2 North America Neurodegenerative Diseases Sales and Growth Rate (2013-2018)
4.3 Europe Neurodegenerative Diseases Sales and Growth Rate (2013-2018)
4.4 Asia-Pacific Neurodegenerative Diseases Sales and Growth Rate (2013-2018)
4.5 South America Neurodegenerative Diseases Sales and Growth Rate (2013-2018)
4.6 Middle East and Africa Neurodegenerative Diseases Sales and Growth Rate (2013-2018)
5 North America Neurodegenerative Diseases by Countries
5.1 North America Neurodegenerative Diseases Sales, Revenue and Market Share by Countries
5.1.1 North America Neurodegenerative Diseases Sales and Market Share by Countries (2013-2018)
5.1.2 North America Neurodegenerative Diseases Revenue and Market Share by Countries (2013-2018)
5.2 United States Neurodegenerative Diseases Sales and Growth Rate (2013-2018)
5.3 Canada Neurodegenerative Diseases Sales and Growth Rate (2013-2018)
5.4 Mexico Neurodegenerative Diseases Sales and Growth Rate (2013-2018)
6 Europe Neurodegenerative Diseases by Countries
6.1 Europe Neurodegenerative Diseases Sales, Revenue and Market Share by Countries
6.1.1 Europe Neurodegenerative Diseases Sales and Market Share by Countries (2013-2018)
6.1.2 Europe Neurodegenerative Diseases Revenue and Market Share by Countries (2013-2018)
6.2 Germany Neurodegenerative Diseases Sales and Growth Rate (2013-2018)
6.3 UK Neurodegenerative Diseases Sales and Growth Rate (2013-2018)
6.4 France Neurodegenerative Diseases Sales and Growth Rate (2013-2018)
6.5 Russia Neurodegenerative Diseases Sales and Growth Rate (2013-2018)
6.6 Italy Neurodegenerative Diseases Sales and Growth Rate (2013-2018)
7 Asia-Pacific Neurodegenerative Diseases by Countries
7.1 Asia-Pacific Neurodegenerative Diseases Sales, Revenue and Market Share by Countries
7.1.1 Asia-Pacific Neurodegenerative Diseases Sales and Market Share by Countries (2013-2018)
7.1.2 Asia-Pacific Neurodegenerative Diseases Revenue and Market Share by Countries (2013-2018)
7.2 China Neurodegenerative Diseases Sales and Growth Rate (2013-2018)
7.3 Japan Neurodegenerative Diseases Sales and Growth Rate (2013-2018)
7.4 Korea Neurodegenerative Diseases Sales and Growth Rate (2013-2018)
7.5 India Neurodegenerative Diseases Sales and Growth Rate (2013-2018)
7.6 Southeast Asia Neurodegenerative Diseases Sales and Growth Rate (2013-2018)
8 South America Neurodegenerative Diseases by Countries
8.1 South America Neurodegenerative Diseases Sales, Revenue and Market Share by Countries
8.1.1 South America Neurodegenerative Diseases Sales and Market Share by Countries (2013-2018)
8.1.2 South America Neurodegenerative Diseases Revenue and Market Share by Countries (2013-2018)
8.2 Brazil Neurodegenerative Diseases Sales and Growth Rate (2013-2018)
8.3 Argentina Neurodegenerative Diseases Sales and Growth Rate (2013-2018)
8.4 Colombia Neurodegenerative Diseases Sales and Growth Rate (2013-2018)
9 Middle East and Africa Neurodegenerative Diseases by Countries
9.1 Middle East and Africa Neurodegenerative Diseases Sales, Revenue and Market Share by Countries
9.1.1 Middle East and Africa Neurodegenerative Diseases Sales and Market Share by Countries (2013-2018)
9.1.2 Middle East and Africa Neurodegenerative Diseases Revenue and Market Share by Countries (2013-2018)
9.2 Saudi Arabia Neurodegenerative Diseases Sales and Growth Rate (2013-2018)
9.3 UAE Neurodegenerative Diseases Sales and Growth Rate (2013-2018)
9.4 Egypt Neurodegenerative Diseases Sales and Growth Rate (2013-2018)
9.5 Nigeria Neurodegenerative Diseases Sales and Growth Rate (2013-2018)
9.6 South Africa Neurodegenerative Diseases Sales and Growth Rate (2013-2018)
10 Global Neurodegenerative Diseases Market Segment by Type
10.1 Global Neurodegenerative Diseases Sales, Revenue and Market Share by Type (2013-2018)
10.1.1 Global Neurodegenerative Diseases Sales and Market Share by Type (2013-2018)
10.1.2 Global Neurodegenerative Diseases Revenue and Market Share by Type (2013-2018)
10.2 NMDA Sales Growth and Price
10.2.1 Global NMDA Sales Growth (2013-2018)
10.2.2 Global NMDA Price (2013-2018)
10.3 SSRIs Sales Growth and Price
10.3.1 Global SSRIs Sales Growth (2013-2018)
10.3.2 Global SSRIs Price (2013-2018)
10.4 Dopamine Inhibitors Sales Growth and Price
10.4.1 Global Dopamine Inhibitors Sales Growth (2013-2018)
10.4.2 Global Dopamine Inhibitors Price (2013-2018)
11 Global Neurodegenerative Diseases Market Segment by Application
11.1 Global Neurodegenerative Diseases Sales Market Share by Application (2013-2018)
11.2 Parkinson’s disease Sales Growth (2013-2018)
11.3 Huntington disease Sales Growth (2013-2018)
11.4 Amyotrophic Lateral Sclerosis Sales Growth (2013-2018)
11.5 Alzheimer’s disease Sales Growth (2013-2018)
12 Neurodegenerative Diseases Market Forecast (2018-2023)
12.1 Global Neurodegenerative Diseases Sales, Revenue and Growth Rate (2018-2023)
12.2 Neurodegenerative Diseases Market Forecast by Regions (2018-2023)
12.2.1 North America Neurodegenerative Diseases Market Forecast (2018-2023)
12.2.2 Europe Neurodegenerative Diseases Market Forecast (2018-2023)
12.2.3 Asia-Pacific Neurodegenerative Diseases Market Forecast (2018-2023)
12.2.4 South America Neurodegenerative Diseases Market Forecast (2018-2023)
12.2.5 Middle East and Africa Neurodegenerative Diseases Market Forecast (2018-2023)
12.3 Neurodegenerative Diseases Market Forecast by Type (2018-2023)
12.3.1 Global Neurodegenerative Diseases Sales Forecast by Type (2018-2023)
12.3.2 Global Neurodegenerative Diseases Market Share Forecast by Type (2018-2023)
12.4 Neurodegenerative Diseases Market Forecast by Application (2018-2023)
12.4.1 Global Neurodegenerative Diseases Sales Forecast by Application (2018-2023)
12.4.2 Global Neurodegenerative Diseases Market Share Forecast by Application (2018-2023)
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.1.3 Marketing Channel Future Trend
13.2 Distributors, Traders and Dealers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Data Source
List of Tables and Figures
Figure Neurodegenerative Diseases Picture
Table Product Specifications of Neurodegenerative Diseases
Figure Global Sales Market Share of Neurodegenerative Diseases by Types
ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems
Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system
Global Outreach6 Major regions and 40+ countries level analysis accomplished
Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery
